IP Library › Granted Patent US 12,493,035
Granted Patent B2
US 12,493,035 · App. 17/451,900 · Granted Dec 9, 2025

Cellular vamp cleavage assay

Inventors: Bryony Gray (Wrexham, GB); Verity Cadd (Wrexham, GB); Matthew Beard (Wrexham, GB)
Assignee: Ipsen Biopharm Limited
G01N33/56911C07K14/33C07K14/47C07K16/1282C07K16/18C12Q1/37C07K2317/30C07K2317/92C07K2319/00G01N2333/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,493,035
App. No.
17/451,900
Filed
Oct 22, 2021
Granted
Dec 9, 2025
Kind
B2
Art Unit
1645
USPC
435/7.32
Abstract

A method for determining cleavage of a VAMP by a clostridial neurotoxin in a cell that has been contacted with the clostridial neurotoxin under conditions suitable for clostridial neurotoxin activity, the method comprising contacting the cytoplasmic content of the cell with an antibody that binds to a resulting C-terminal product of such cleavage under suitable conditions in vitro or ex vivo and detecting the binding of the antibody to the C-terminal cleavage product. The antibody may, for example, be capable of binding an antigenic polypeptide consisting of 10 to 65 amino acid residues and comprising an epitope comprising an amino acid sequence that is at least 90% identical to an amino acid sequence of at least 8 amino acid residues that is immediately C-terminal to a clostridial neurotoxin cleavage site in the VAMP.

Claims (26)

1 . A method for determining cleavage in a cell of a VAMP into C-terminal and N-terminal cleavage products by a VAMP-cleaving clostridial neurotoxin, the method comprising:

a) contacting the cell with the clostridial neurotoxin under conditions suitable for clostridial neurotoxin activity;

b) contacting the cytoplasmic content of the cell in vitro or ex vivo with a first antibody that binds to the C-terminal VAMP cleavage product under suitable binding conditions; and

c) detecting the binding of the first antibody to the C-terminal VAMP-cleavage product.

2 . The method of claim 1 , further comprising:

d) quantifying the amount of the C-terminal cleavage product bound to the first antibody.

3 . The method of claim 1 , wherein the first antibody is capable of binding an antigenic polypeptide that: a) consists of 10 to 65 amino acid residues; and b) comprises an epitope comprising an amino acid sequence that is at least 90% identical to a sequence comprising at least 8 amino acid residues that is immediately C-terminal to a clostridial neurotoxin cleavage site in the VAMP.

4 . The method of claim 3 , wherein the antigenic-polypeptide consists of 10 to 17 amino acid residues.

5 . The method of claim 3 , wherein the VAMP is VAMP1, VAMP2, VAMP3, VAMP4, VAMP5, or YKT6.

6 . The method of claim 3 , wherein the epitope comprises an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 15-34 and 48-78.

7 . The method of claim 3 , wherein the epitope comprises an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 62, 66, and 75.

8 . The method of claim 1 , wherein step b) further comprises contacting the cytoplasmic content of the cell with a second antibody that binds to the full-length VAMP under suitable binding conditions and step c) further comprises detecting the binding of the second antibody to the full-length VAMP.

9 . The method of claim 8 , further comprising:

d) quantifying the amount of the C-terminal cleavage product bound to the first antibody and the amount of the full-length VAMP bound to the second antibody.

10 . The method of claim 8 , wherein the second antibody is not capable of binding to the C-terminal cleavage product.

11 . The method of claim 10 , wherein the second antibody binds to the N-terminal VAMP cleavage product.

12 . The method of claim 1 , wherein the first antibody also binds to full-length VAMP and the method further comprises:

d) quantifying the amount of the C-terminal cleavage product bound to the first antibody and the amount of full-length VAMP bound to the first antibody.

13 . The method of claim 1 , wherein the cell is a mammalian cell.

14 . The method of claim 1 , wherein the cell is a neuronal cell.

15 . The method of claim 1 , wherein the cell expresses high levels of synaptotagmin I, synaptotagmin II, and/or synaptic vesicle protein.

16 . The method of claim 1 , wherein the cell is contacted with the clostridial neurotoxin at about 37° C. for a period of from about 1 hour to about 48 hours.

17 . The method of claim 1 , wherein the cytoplasmic content of the cell is incubated with the first antibody at about 4° C. for a period of from about 8 hours to about 48 hours or at about 25° C. for a period of from about 30 minutes to about 8 hours.

18 . The method of claim 1 , wherein the detection is by Western blot or enzyme-linked immunosorbent assay.

19 . The method of claim 1 , wherein the cell is lysed or permeabilized before the cytoplasmic content thereof is contacted with the first antibody.

20 . The method of claim 1 , wherein the clostridial neurotoxin is BoNT/X.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2021
From: GRAY, BRYONY; CADD, VERITY; FOSTER, KEITH
To: IPSEN BIOPHARM LIMITED
Reel/Frame 058490/0112 →
Priority Claims (1)
EP 16194390 · Oct 18, 2016 · regional
Continuity (2)
Division 16335358
Related Publication 20220113310A1 · Apr 14, 2022
References Cited (33)
US 5962637A · Shone · 1999 [cited by examiner]
US 7227010B2 · Smith · 2007 [cited by applicant]
US 9562903B2 · Kalkun et al. · 2017 [cited by applicant]
US 20040126810A1 · Roques et al. · 2004 [cited by applicant]
US 20060024763A1 · Schmidt et al. · 2006 [cited by applicant]
US 20070104737A1 · Smith · 2007 [cited by applicant]
US 20120164657A1 · Johnson et al. · 2012 [cited by applicant]
US 20130345398A1 · Smith et al. · 2013 [cited by applicant]
US 20140287433A1 · Weingart et al. · 2014 [cited by applicant]
US 20190219575A1 · Gray et al. · 2019 [cited by applicant]
EP 0763131 · 1995 [cited by examiner]
EP 0763131B1 · 1999 [cited by applicant]
WO 9734620A1 · 1997 [cited by applicant]
WO WO03001206A1 · 2003 [cited by examiner]
WO 2013011055A1 · 2013 [cited by applicant]
WO 2018073288A1 · 2018 [cited by applicant]
Moghaddam et al (Biologicals, 2010, 38:113-119) (Year: 2010). [cited by examiner]
Moghaddam et al., Biologicals, 38:113-119 (2010). [cited by applicant]
Binz et al., Toxins, 2:665-682 (2010). [cited by applicant]
Sikorra et al., J. Biol. Chem., 283:21145-21152 (2008). [cited by applicant]
Hallis et al., Journal of Clinical Microbiology, 34:1934-1938 (1996). [cited by applicant]
Wictome et al., Applied and Environmental Microbiology, 65:3787-3792 (1999). [cited by applicant]
Kegel et al., Toxicology In Vitro, 21:1641-1649 (2007). [cited by applicant]
Kalb et al., FEBs Letters, 586:109-115 (2011). [cited by applicant]
Pellett et al., FEBs Letters, 581:4803-4808 (2007). [cited by applicant]
Gray et al., Toxicology in Vitro, 48:255-261 (2018). [cited by applicant]
Hackett et al, Toxins, 10:195 (2018). [cited by applicant]
Kozaki et al, Infection and Immunity, 66:4811-4816 (1998). [cited by applicant]
Masuyer et al., Journal of Structural Biology, 174:52-57 (2011). [cited by applicant]
Peng et al., PLOS Pathogens, 10:e1004177 (2014). [cited by applicant]
Rao et al., J. Biol. Chem., 279:20471-20479 (2004). [cited by applicant]
Rossetto et al., Nature, 72:415-416 (1994). [cited by applicant]
Savage et al., Toxins, 7:1544-1555 (2015). [cited by applicant]